We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where BridgeBio Pharma Inc. (NASDAQ:BBIO) stands against the other stocks.
Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno ...
The company has debuted its newest venture—GondolaBio, a biopharma startup. It will focus on developing therapies for genetic and rare diseases. Overall BBIO ranks 12th on our list of the best ...
and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of ...
For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several years – but fell to $1.6 billion across Q2 and Q3 combined ...
The FDA today issued a notice informing customers of updated instructions for the Johnson & Johnson Abiomed Impella RP heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback